ERAS (Erasca, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ERAS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-12 | Charles S. Fuchs | President, R&D | A | — | — |
| 2026-06-29 | Julie Hambleton | Director | A | — | — |
| 2026-06-29 | Alexander W. Casdin | Director | A | — | — |
| 2026-06-29 | Pratik S Multani | Director | A | — | — |
| 2026-06-29 | James Arthur Bristol | Director | A | — | — |
| 2026-06-29 | JEAN I LIU | Director | A | — | — |
| 2026-06-29 | Valerie Denise Harding Start | Director | A | — | — |
| 2026-04-03 | Ebun Garner | Chief Legal Officer | MIXED | — | — |
| 2026-03-06 | Shannon Morris | Chief Medical Officer | MIXED | — | — |
| 2026-01-30 | Jonathan E Lim | Chairman & CEO | A | — | — |
| 2026-01-30 | David M. Chacko | CFO and CBO | J | — | — |
| 2026-01-30 | Shannon Morris | Chief Medical Officer | A | — | — |
| 2026-01-30 | Ebun Garner | General Counsel & Corp. Sec. | A | — | — |
| 2026-01-30 | Michael David Varney | Director | A | — | — |
| 2026-01-08 | Ebun Garner | General Counsel & Corp. Sec. | MIXED | — | — |
| 2026-01-05 | Pratik S Multani | Director | A | — | — |
| 2026-01-05 | JEAN I LIU | Director | A | — | — |
| 2026-01-05 | Alexander W. Casdin | Director | A | — | — |
| 2026-01-05 | James Arthur Bristol | Director | A | — | — |
| 2026-01-05 | Valerie Denise Harding Start | Director | A | — | — |
| 2025-06-26 | Michael David Varney | Director | A | — | — |
| 2025-06-26 | Valerie Denise Harding Start | Director | A | — | — |
| 2025-06-26 | JEAN I LIU | Director | A | — | — |
| 2025-06-26 | Pratik S Multani | Director | A | — | — |
| 2025-06-26 | Alexander W. Casdin | Director | A | — | — |
| 2025-06-26 | James Arthur Bristol | Director | A | — | — |
| 2025-06-26 | Julie Hambleton | Director | A | — | — |
| 2025-06-03 | Pratik S Multani | Director | G | — | — |
| 2025-02-18 | Ebun Garner | General Counsel & Corp. Sec. | A | — | — |
| 2025-02-05 | Shannon Morris | Chief Medical Officer | A | — | — |
| 2025-02-05 | Jonathan E Lim | Chairman & CEO | A | — | — |
| 2025-02-05 | David M. Chacko | CFO and CBO | J | — | — |
| 2025-02-05 | Ebun Garner | General Counsel & Corp. Sec. | J | — | — |
| 2025-01-02 | Valerie Denise Harding Start | Director | A | — | — |
| 2025-01-02 | James Arthur Bristol | Director | A | — | — |
| 2025-01-02 | Alexander W. Casdin | Director | A | — | — |
| 2025-01-02 | JEAN I LIU | Director | A | — | — |
| 2024-06-21 | Jonathan E Lim | Chairman & CEO | A | — | — |
| 2024-06-21 | Shannon Morris | Chief Medical Officer | A | — | — |
| 2024-06-21 | Pratik S Multani | Director | A | — | — |
| 2024-06-21 | Julie Hambleton | Director | A | — | — |
| 2024-06-21 | Ebun Garner | General Counsel & Corp. Sec. | A | — | — |
| 2024-06-21 | JEAN I LIU | Director | A | — | — |
| 2024-06-21 | Valerie Denise Harding Start | Director | A | — | — |
| 2024-06-21 | Michael David Varney | Director | A | — | — |
| 2024-06-21 | David M. Chacko | CFO and CBO | A | — | — |
| 2024-06-21 | James Arthur Bristol | Director | A | — | — |
| 2024-06-21 | Alexander W. Casdin | Director | A | — | — |
| 2024-05-22 | Alexander W. Casdin | Director | Buy | — | — |
| 2024-02-07 | Jonathan E Lim | Chairman & CEO | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chairman & CEO | 19,456,216 | — |
| — | 10%+ Owner | 11,899,360 | — |
| — | Director | 10,813,246 | — |
| — | Director | 10,813,246 | — |
| — | 10%+ Owner | 10,505,553 | — |
| — | 10%+ Owner | 5,527,777 | — |
| — | Director | 667,724 | — |
| — | Chief Medical Officer | 315,812 | — |
| — | CFO and CBO | 279,980 | — |
| — | Director | 207,500 | — |
| — | Director | 172,866 | — |
| — | Chief Legal Officer | 105,076 | — |
| — | Director | 22,000 | — |
| — | Director | 6,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ERAS quote page; the site-wide leaderboard is on the insider transactions hub.